HER-2 expression

Our HI-MAE model opens new avenues for future research, facilitating the incorporation of IHC information into other classification tasks, particularly for precise biomarker predictions.Clinical relevance- By incorporating IHC images into the pre-training process, we enable the prediction of HER2 status directly from routine H&E-stained tissue sections under the guidance of IHC information, thereby eliminating the need for IHC images during the testing phase. This approach significantly reduces the staining costs associated with IHC.

Understanding the mechanisms underlying BRCA1-mediated lineage plasticity offers novel therapeutic avenues to target early-stage tumor initiation and progression in BRCA1-mutated breast cancer. This review perspective sheds light on the role of BRCA1 in lineage plasticity and highlights probable mechanisms by which BRCA1 could promote this lineage plasticity.

In a neoadjuvant immunotherapy real-world cohort (n = 111), HER2-low primary tumors had lower midcourse (28% vs. 44%) and pathological complete response (64% vs. 72%) compared to HER2-0. These findings show that HER2 expression defines immune-cold HER2-negative EBC, hindering immunotherapy and supporting HER2-targeted combination in HER2-low EBC patients.

P1, N=123, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2026 --> May 2026 | Trial primary completion date: Dec 2026 --> May 2026

Differential expression analysis and co-expression network construction revealed 154 candidate TEX-related genes, from which five prognostically significant genes were selected to construct a risk scoring model.ResultsOur findings indicate that TEX characteristics are crucial for prognostic assessment in TNBC patients, with significant correlations between risk scores and tumor-infiltrating immune cells. High-risk patients exhibited elevated expression levels of immune checkpoint genes, suggesting potential implications for immunotherapy.ConclusionsThis study underscores the clinical significance of TEX features in TNBC prognosis and highlights the urgent need for therapeutic strategies targeting TEX to improve patient outcomes.

HER2DX reflects key biological and pathological features of HER2+ breast cancer and independently predicts pCR, supporting its utility for individualized treatment decision-making.

Our model, based on NIH 3T3 cells, became sensitive to the monoclonal antibody trastuzumab and to the selective HER2 tyrosine kinase inhibitor tucatinib. The results suggest that this model could be a promising tool for preclinical functional cross-reactivity tests of anti-HER2 therapies before in vivo studies.

These findings highlight the dual role of fascin in tumor cells and the tumor microenvironment (TME), and reinforce its potential as a biomarker for personalized TNBC therapies. Ongoing clinical trials, including HITCLIF, are exploring the efficacy of imipramine in patients with fascin-overexpressing cancers, paving the way for targeted treatment strategies.

We have measured C/EBPβ's suppression of metastasis in traditional cell culture under hypoxic conditions and in vivo. These results point toward a novel approach to C/EBPβ's contradictory role as a driver and mediator of metastasis, and a potential therapeutic for its treatment.

Treatment with the PI3K inhibitor LY294002 effectively inhibited p-PI3K activation and substantially reduced HER2 expression. Immunohistochemistry (IHC) analysis confirmed a strong positive correlation between changes in HER2 expression and tumor radioactive uptake trends. This study highlights the pivotal role of HER2 as a dynamic biomarker in trastuzumab resistance and supports the integration of molecular imaging into clinical decision-making for personalized therapeutic adjustments in HER2-positive breast cancer.

HER2-ultralow tumors represent a distinct subgroup characterized by higher hormone receptor positivity, whereas HER2-null tumors were associated with younger age, higher TIL density, and poorer survival. These findings emphasize the clinical significance of refining HER2-negative subclassification to distinguish HER2-ultralow, while acknowledging limitations of sample size and retrospective design.

Temporal analysis showed conversion rates of 50.0% for synchronous metastases, 30.8% within 12 months, and 63.6% beyond 12 months. We identified a high prevalence of HER2-low and HER2-ultralow subtypes, suggesting potential eligibility for ADC therapies.